• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    2/26/24 12:31:06 PM ET
    $ACON
    $AKLI
    $BBLG
    $BFLY
    Medical Specialities
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ACON alert in real time by email

    Gainers

    • Akili (NASDAQ:AKLI) shares rose 121.1% to $0.49 during Monday's regular session. The market value of their outstanding shares is at $38.3 million.
    • ZyVersa Therapeutics (NASDAQ:ZVSA) stock rose 69.78% to $1.36. The company's market cap stands at $6.2 million.
    • Ocean Biomedical (NASDAQ:OCEA) stock increased by 66.24% to $2.61. The company's market cap stands at $88.9 million.
    • Krystal Biotech (NASDAQ:KRYS) stock moved upwards by 39.37% to $155.16. The company's market cap stands at $4.3 billion. The company's, Q4 earnings came out today.
    • Milestone Pharmaceuticals (NASDAQ:MIST) shares increased by 38.23% to $2.35. The company's market cap stands at $78.6 million.
    • Butterfly Network (NYSE:BFLY) shares moved upwards by 36.27% to $1.39. The market value of their outstanding shares is at $287.9 million.

    Losers

    • Aclarion (NASDAQ:ACON) stock decreased by 63.0% to $0.34 during Monday's regular session.
    • Venus Concept (NASDAQ:VERO) stock fell 25.41% to $0.97. The company's market cap stands at $5.3 million.
    • ThermoGenesis Holdings (NASDAQ:THMO) shares fell 22.86% to $0.81. The company's market cap stands at $2.5 million.
    • Bone Biologics (NASDAQ:BBLG) shares decreased by 20.7% to $2.85. The company's market cap stands at $1.5 million.
    • NGM Biopharmaceuticals (NASDAQ:NGM) stock declined by 19.51% to $1.54. The market value of their outstanding shares is at $127.1 million.
    • Concord Medical Services (NYSE:CCM) stock fell 18.94% to $0.43. The company's market cap stands at $18.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON
    $AKLI
    $BBLG
    $BFLY

    CompanyDatePrice TargetRatingAnalyst
    Krystal Biotech Inc.
    $KRYS
    1/6/2026$309.00Neutral → Buy
    Citigroup
    Milestone Pharmaceuticals Inc.
    $MIST
    12/15/2025$8.00Hold → Buy
    TD Cowen
    Milestone Pharmaceuticals Inc.
    $MIST
    9/11/2025$4.00Overweight
    Wells Fargo
    Butterfly Network Inc.
    $BFLY
    8/1/2025Outperform → Perform
    Oppenheimer
    Butterfly Network Inc.
    $BFLY
    7/1/2025$3.00Buy
    Craig Hallum
    Milestone Pharmaceuticals Inc.
    $MIST
    6/5/2025$5.00Buy
    H.C. Wainwright
    Butterfly Network Inc.
    $BFLY
    3/17/2025Outperform
    William Blair
    Krystal Biotech Inc.
    $KRYS
    3/5/2025$245.00Buy
    Jefferies
    More analyst ratings

    $ACON
    $AKLI
    $BBLG
    $BFLY
    SEC Filings

    View All

    Bone Biologics Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Bone Biologics Corp (0001419554) (Filer)

    3/13/26 4:35:42 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    SEC Form 424B5 filed by Bone Biologics Corp

    424B5 - Bone Biologics Corp (0001419554) (Filer)

    3/13/26 4:31:10 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    SEC Form 144 filed by Butterfly Network Inc.

    144 - Butterfly Network, Inc. (0001804176) (Subject)

    3/5/26 4:42:18 PM ET
    $BFLY
    Medical Electronics
    Health Care

    $ACON
    $AKLI
    $BBLG
    $BFLY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Phanstiel S. Louise bought $571,160 worth of shares (185,261 units at $3.08) (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    12/17/25 4:10:13 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Director Robbins Larry bought $64,471 worth of shares (21,370 units at $3.02) (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    12/15/25 6:20:36 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Director Robbins Larry bought $4,652,773 worth of shares (1,558,541 units at $2.99) (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    12/5/25 5:40:49 PM ET
    $BFLY
    Medical Electronics
    Health Care

    $ACON
    $AKLI
    $BBLG
    $BFLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Goux Laurent Louis Jean claimed ownership of 919 shares (SEC Form 3)

    3 - Krystal Biotech, Inc. (0001711279) (Issuer)

    3/6/26 6:26:21 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Thomas John Charles claimed ownership of 642 shares (SEC Form 3)

    3 - Krystal Biotech, Inc. (0001711279) (Issuer)

    3/6/26 6:24:44 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President, R&D Krishnan Suma sold $6,580,270 worth of shares (25,000 units at $263.21), decreasing direct ownership by 2% to 1,403,155 units (SEC Form 4)

    4 - Krystal Biotech, Inc. (0001711279) (Issuer)

    3/6/26 6:23:09 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $AKLI
    $BBLG
    $BFLY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026

    MONTREAL and CHARLOTTE, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) today announced that it will report fourth quarter and full-year 2025 results and provide a business update on Friday, March 20, 2026, before the market opens. The announcement will be followed by a conference call and webcast for investors at 8:30am ET. Conference Details: Conference Dial-in:1-877-407-0792International Dial-in:1-201-689-8263Conference ID:13759195Webcast link:click here Call me™: Participants can use Guest dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. The Call me™ link will be made acti

    3/12/26 8:00:00 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclarion CEO Brent Ness to Attend LSI USA 2026

    BROOMFIELD, Colo., March 12, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that Brent Ness, Chief Executive Officer, will be attending LSI USA 2026, one of the leading conferences of global MedTech innovators, investors, and industry leaders. During the event, Mr. Ness will meet with investors and potential industry partners to discuss Aclarion's continued progress advancing NOCISCAN, the company's proprietary MR spectroscopy pl

    3/12/26 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Butterfly Network Appoints David Horsley as Senior Vice President, Innovation – Butterfly Embedded™

    Chirp Microsystems Co-Founder Joins Butterfly to Advance its Ultrasound-on-Chip™ Platform Strategy Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of David Horsley, Ph.D. as Senior Vice President of Innovation – Butterfly Embedded™ to scale its Ultrasound-on-Chip™ co-development and licensing initiative. In this role, Dr. Horsley will lead strategy and go-to-market for Butterfly Embedded, overseeing new product development, partnerships, and commercialization efforts. Butterfly Embedded is focused on extending the reach of the company's proprietary semic

    3/10/26 8:05:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    $ACON
    $AKLI
    $BBLG
    $BFLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Krystal Biotech upgraded by Citigroup with a new price target

    Citigroup upgraded Krystal Biotech from Neutral to Buy and set a new price target of $309.00

    1/6/26 8:26:47 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Milestone Pharmaceuticals upgraded by TD Cowen with a new price target

    TD Cowen upgraded Milestone Pharmaceuticals from Hold to Buy and set a new price target of $8.00

    12/15/25 10:09:22 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Milestone Pharmaceuticals with a new price target

    Wells Fargo initiated coverage of Milestone Pharmaceuticals with a rating of Overweight and set a new price target of $4.00

    9/11/25 8:45:07 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $AKLI
    $BBLG
    $BFLY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 19, 2023 - FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa

    For Immediate Release: May 19, 2023 Today, the U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.  “Vyjuvek is the first FDA-approved gene therapy treatment for DEB, a

    5/19/23 1:48:20 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $AKLI
    $BBLG
    $BFLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Krystal Biotech Inc.

    SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)

    11/14/24 9:00:58 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

    SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

    11/14/24 7:19:34 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by ZyVersa Therapeutics Inc.

    SC 13G/A - ZyVersa Therapeutics, Inc. (0001859007) (Subject)

    11/14/24 6:01:27 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $AKLI
    $BBLG
    $BFLY
    Financials

    Live finance-specific insights

    View All

    Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026

    MONTREAL and CHARLOTTE, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) today announced that it will report fourth quarter and full-year 2025 results and provide a business update on Friday, March 20, 2026, before the market opens. The announcement will be followed by a conference call and webcast for investors at 8:30am ET. Conference Details: Conference Dial-in:1-877-407-0792International Dial-in:1-201-689-8263Conference ID:13759195Webcast link:click here Call me™: Participants can use Guest dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. The Call me™ link will be made acti

    3/12/26 8:00:00 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Butterfly Network Reports Fourth Quarter 2025 Financial Results

    Delivered Record Annual and Quarterly Revenue Reported quarterly record Revenue of $31.5 million in Q4, representing 41% YoY growth Generated positive net cash flow of $6.3 million in Q4 and lowest annual cash usage in company history Midjourney partnership contributed $6.8 million of revenue in Q4, advancing Butterfly Embedded™ platform strategy Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with semiconductor chip-based ultrasound devices, software and AI, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. Joseph DeVivo, Butterfly's Presiden

    2/26/26 6:30:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

    $107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment of HHD Strong balance sheet, ending the quarter with $955.9 million in cash and investments PITTSBURGH, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today reported financial results for the fourth quarter and full year ending December 31, 2025 and provided a business update. "In 2025, Krystal made meaningful progress on our mission to serve patients with dystrophic epidermolysis bullosa around the world, while continuing to build the global infrastructure req

    2/17/26 7:00:00 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $AKLI
    $BBLG
    $BFLY
    Leadership Updates

    Live Leadership Updates

    View All

    Butterfly Network Appoints David Horsley as Senior Vice President, Innovation – Butterfly Embedded™

    Chirp Microsystems Co-Founder Joins Butterfly to Advance its Ultrasound-on-Chip™ Platform Strategy Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of David Horsley, Ph.D. as Senior Vice President of Innovation – Butterfly Embedded™ to scale its Ultrasound-on-Chip™ co-development and licensing initiative. In this role, Dr. Horsley will lead strategy and go-to-market for Butterfly Embedded, overseeing new product development, partnerships, and commercialization efforts. Butterfly Embedded is focused on extending the reach of the company's proprietary semic

    3/10/26 8:05:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

    MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval's appointment comes as Milestone launches CARDAMYST™ (etripamil) nasal spray, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025. He will serve as a member of Milestone's executive leadership team and will provide business-focused legal counsel across all

    2/10/26 8:00:00 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

    Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companiesStrong track record of launching breakthrough technologies across spine, neurosurgery and pain managementStrengthens Aclarion's commercial execution as the Company expands adoption and payer engagement across the Eastern U.S. BROOMFIELD, Colo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the

    12/2/25 8:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care